CGEM
NASDAQCullinan Therapeutics Inc.
News · 26 weeks61-30%
2025-12-142026-06-07
Mix2290d
- SEC Filings11(50%)
- Other8(36%)
- Earnings2(9%)
- Insider1(5%)
Latest news
25 items- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 CongressClinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan's Immunology Day on June 10 CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential firs
- PRCullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell EngagerNew and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies Initial data from the first multi-dose cohort of RA study to be presented Initial data from the first multi-dose cohort of velinotamig study also to be shared Leading key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser to share clinical perspectives The Company will host the in-person event for analysts and institutional investors on Wednesday, June 10, starting at 8:30 a.m. ET in New York City CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biop
- PRCullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid LeukemiaOrphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CLN-049, a novel, investigational FLT3xCD3 T cell engager, for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). "FDA Orphan Drug Designation for CLN-049 emphasizes both the urgent need for n
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 CongressCAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology being held June 3-6, 2026 in London, United Kingdom. The presentation will feature data from the Phase 1 OUTRACE RA and OUTRACE SLE studies which are evaluating CLN-978 in patients with
- PRThe Biology Came First.Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today. MindWalk Holdings Corp. (NASDAQ:HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cullinan Therapeutics Inc.SCHEDULE 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)
- SECSEC Form 10-Q filed by Cullinan Therapeutics Inc.10-Q - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsInitial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by U.S. FDA; PDUFA target action date of February 27, 2027 Cash and investments of $393.3 million as of March 31, 2026; runway into 2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights
- INSIDERChief Scientific Officer Michaelson Jennifer exercised 4,000 shares at a strike of $4.30 and sold $116,996 worth of shares (8,000 units at $14.62) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 166,844 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- SECSEC Form 144 filed by Cullinan Therapeutics Inc.144 - Cullinan Therapeutics, Inc. (0001789972) (Subject)
- SECSEC Form S-3ASR filed by Cullinan Therapeutics Inc.S-3ASR - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRU.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNDA submission based on the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meaningful and durable responses in patients with relapsed EGFR exon 20 insertion–mutated NSCLC Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027 Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations whose disease h
- SECSEC Form DEFA14A filed by Cullinan Therapeutics Inc.DEFA14A - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- SECSEC Form DEF 14A filed by Cullinan Therapeutics Inc.DEF 14A - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cullinan Therapeutics Inc.SCHEDULE 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)
- SECSEC Form S-8 filed by Cullinan Therapeutics Inc.S-8 - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- SECSEC Form 10-K filed by Cullinan Therapeutics Inc.10-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- SECCullinan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
- PRCullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsInitial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its fin
- INSIDERChief Scientific Officer Michaelson Jennifer sold $125,440 worth of shares (8,000 units at $15.68) and exercised 4,000 shares at a strike of $4.30, decreasing direct ownership by 2% to 170,844 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Cullinan Therapeutics Inc.SCHEDULE 13G - Cullinan Therapeutics, Inc. (0001789972) (Subject)
- INSIDERChief Scientific Officer Michaelson Jennifer sold $25,169 worth of shares (1,780 units at $14.14), decreasing direct ownership by 1% to 174,844 units (SEC Form 4)4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
CGEM FAQ
7 questionsWhat does Cullinan Therapeutics Inc. do?
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the...Where does CGEM stock trade?
Cullinan Therapeutics Inc. (CGEM) is listed on NASDAQ.What sector and industry is CGEM in?
Cullinan Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Cullinan Therapeutics Inc. go public?
Cullinan Therapeutics Inc. (CGEM) completed its IPO in 2021.What are analysts saying about CGEM?
Cullinan Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $3300.00 price target on 2026-02-17. Recent price targets range from $2200.00 to $4000.00.What companies are similar to CGEM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CGEM side-by-side with any of them on Quantisnow.How can I track CGEM on Quantisnow?
Quantisnow aggregates Cullinan Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGEM to receive live email and push alerts on every new disclosure.